AKT1 and hepatocellular carcinoma: Aldob inhibits Akt activity and downstream signaling events, which leads to cell cycle arrest and the impairment of glucose consumption and metabolic flux to glycolysis and TCA cycle, thereby suppressing HCC cell proliferation and tumorigenesis.